SAN FRANCISCO–(BUSINESS WIRE)–$SPRB #CAH—Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in November.
Credit Suisse 31st Annual Healthcare Conference
Date: November 7-10, 2022
Format: Company presentation (November 8, 2022 at 2:35 p.m. PT) and 1×1 meetings
Jefferies 2022 London Healthcare Conference
Date: November 15-17, 2022
Format: 1×1 meetings
Interested parties can access the webcast for conference presentations from the events section of the company’s investor relations website. A replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 60 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
Contacts
Media Contact
Will Zasadny
Canale Communications
(619) 961-8848
[email protected]
[email protected]
Investors
Xuan Yang
Solebury Strategic Communications
(415) 971-9412
[email protected]
[email protected]
